Swiss Biotech Stock News

Barry Callebaut (SWX:BARN) has released its H1 2026 scorecard with Total Revenue of CHF 7.5b and Basic EPS of CHF 28.03 in the second half of 2025, alongside CHF 7.3b of revenue and EPS of CHF 5.85 in the first half. Trailing twelve month EPS stands at CHF 33.90 on CHF 14.8b of revenue, framing the latest read on profitability. The company’s Total Revenue has increased from CHF 5.7b and EPS of CHF 20.40 in H2 2024 to the current H2 2025 levels, drawing investor attention to how slim margins...

Why Temenos Is On Investors’ Radar Today Temenos (SWX:TEMN) is drawing attention after a recent share price move, with the stock up 3% over the past day and about 10.5% over the past week, prompting a closer look at fundamentals. See our latest analysis for Temenos. That short burst of share price momentum, with a 10.53% 7 day share price return and the stock now at CHF77.7, sits against a year to date share price return of a 4.66% decline and a 1 year total shareholder return of 25.64%. This...

If you are wondering whether Roche Holding's current share price still offers value, the key is to look past the headline moves and focus on what different valuation methods are really saying. The stock trades at CHF313.50 after a 1% decline over the last week and 3.2% over the past month, while the 1 year return sits at 26.4% and the 3 and 5 year returns are 25.2% and 18.3% respectively. Recent attention on Roche often centers on its position as a major Swiss pharmaceuticals and biotech...

As European markets rally, buoyed by a U.S.-Iran ceasefire and positive investor sentiment, the pan-European STOXX Europe 600 Index has seen a notable increase of 3.05%. In this environment of cautious optimism, dividend stocks can offer an attractive proposition for investors seeking steady income streams amidst market fluctuations.

Guidance confirmation puts Sika (SWX:SIKA) back in focus Sika (SWX:SIKA) has drawn fresh attention after management reiterated 2026 earnings guidance, signaling an expectation for 1% to 4% sales growth in local currencies and a continued aim to outperform its reference market, including bolt-on acquisitions. See our latest analysis for Sika. The guidance confirmation comes after a sharp short term rebound, with a 7 day share price return of 9.06% and a 30 day share price return of 11.14%,...

Goldman Sachs has revised its view on Schindler Holding (SWX:SCHN), upgrading the stock to a neutral rating from sell. The firm cited factors such as backlog conversion, modernization activity and reduced exposure to China as key reasons for the reassessment. See our latest analysis for Schindler Holding. At a share price of CHF261.0, Schindler Holding has seen a 7 day share price return of 2.55% but a 90 day share price return decline of 10.77%, while the 3 year total shareholder return of...

Switzerland’s Federal Criminal Court has cleared UBS Group of liability in the Mozambique tuna bond money laundering case. The decision relates to alleged misconduct tied to Credit Suisse, which UBS acquired in 2023. The ruling removes a major legal overhang linked to pre acquisition Credit Suisse activities for UBS Group. For investors tracking SWX:UBSG, this court decision lands at a time when the stock is trading at CHF33.48 and has shown strong longer term share price gains, with a...

Roche Holding: recent share performance and business profile Roche Holding (SWX:ROP) has drawn investor interest after a mixed share performance, with a small move higher over the past week set against negative returns over the past month and past 3 months. At a last close of CHF 318.10, Roche sits within the large cap pharmaceuticals and diagnostics group, with a market value of roughly CHF 254.2b and operations spanning Europe, North America, Latin America, Asia, Africa, Australia and New...

ABB (SWX:ABBN) is featured as a major supplier of synchronous condensers as global grid operators invest in equipment to support renewable energy integration. The company is highlighted for coupling these large rotating machines with digital monitoring and control tools for grid stability projects. Growing interest in grid modernization gives ABB additional visibility in a niche segment of transmission infrastructure. For you as an investor, this centers ABB around a key piece of hardware...

It looks like Bucher Industries AG ( VTX:BUCN ) is about to go ex-dividend in the next four days. The ex-dividend date...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see...

Nestlé S.A. ( VTX:NESN ) stock is about to trade ex-dividend in 4 days. The ex-dividend date is commonly two business...

Cosmo Pharmaceuticals N.V. reported that shareholders at its recent Ordinary AGM approved all proposals, including a €2.10 per share dividend, with the ex-dividend date set for 24 April 2026 and payment on 11 May 2026. This broad shareholder backing for both governance items and a cash distribution highlights confidence in the company’s capital allocation approach and cash-generating capacity. We’ll now examine how this newly approved €2.10 dividend and strong shareholder support feed into...

R&S Group Holding AG recently reported its full-year 2025 results, with sales rising to CHF 414.84 million and net income reaching CHF 58.1 million, both higher than the prior year. The improvement in basic earnings per share from continuing operations to CHF 1.56 highlights enhanced profitability on a per-share basis alongside the company’s broader growth. With this earnings-driven backdrop and stronger per-share profitability, we will explore how these results shape R&S Group Holding’s...

In early April 2026, Roche announced that its Elecsys Neurofilament Light Chain (NfL) blood test received CE mark approval for detecting neuroinflammation in adults with relapsing-remitting multiple sclerosis, enabling minimally invasive monitoring via its widely installed cobas instruments. This approval could materially change multiple sclerosis care pathways by shifting more frequent disease monitoring from hospital-based MRI scans to accessible, standardized blood testing. Next, we’ll...

Romande Energie Holding SA's ( VTX:REHN ) solid earnings announcement recently didn't do much to the stock price. We...

Idorsia’s pediatric insomnia data puts daridorexant in the spotlight Idorsia (SWX:IDIA) is back on investors’ radar after reporting statistically significant, dose dependent improvements in sleep time for children with insomnia treated with daridorexant, confirming safety and efficacy in patients as young as ten. See our latest analysis for Idorsia. Despite the positive pediatric insomnia data and the recent leadership change in clinical development, Idorsia’s CHF3.524 share price reflects...

Earlier in April 2026, ams-OSRAM reported stronger-than-expected trading, underpinned by improving margins and increased orders for its optical sensor portfolio in automotive and AI applications. The news highlighted how renewed demand for AI-related optical sensors is starting to influence perceptions of ams-OSRAM’s operational progress despite ongoing balance sheet and profitability challenges. We’ll now examine how this renewed interest in AI-related optical sensors could shape...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

SaltX recently reported that it has completed the first industrial-scale test period of electrified precalcination of Holcim’s cement raw meal at its ECRC facility in Hofors, Sweden, achieving positive calcination results and operational stability while processing around 20 tonnes per test run. This progress, alongside parallel work on electrified sintering and a fully electrified pilot plant targeted for 2028, highlights Holcim’s push to electrify and decarbonize cement production at an...

Earnings highlight and why it matters now R&S Group Holding (SWX:RSGN) just released its full year 2025 results, with sales of CHF 414.84 million, revenue of CHF 417.53 million, and net income of CHF 58.1 million drawing fresh attention to the stock. See our latest analysis for R&S Group Holding. The latest results appear to have kept momentum strong, with the share price at CHF24.2 and a 7 day share price return of 22.84% building on a 90 day share price return of 55.33%. The 3 year total...

Julius Bär Gruppe (SWX:BAER) is in the spotlight after a series of leadership changes, including the planned departure of finance chief Evie Kostakis and new board responsibilities for incoming non executive director Colin Bell. See our latest analysis for Julius Bär Gruppe. The executive reshuffle comes as the stock shows mixed momentum, with a 4.9% 1 month share price return and a 1 year total shareholder return of 33.7% contrasting with weaker recent quarterly performance. If leadership...

Medacta Group (SWX:MOVE) has stepped into an unusual spotlight after being selected to engineer a load bearing hip implant for a resurrected Tyrannosaurus rex as part of an international dinosaur revival project. See our latest analysis for Medacta Group. While the dinosaur project has put Medacta in the headlines, the CHF153.4 share price sits below its recent peak, with short term share price returns weaker. However, a 1 year total shareholder return of 34.52% still points to solid long...

Galderma Group (SWX:GALD) is back in focus after new clinical data on Sculptra and Restylane in menopause and medication driven weight loss, fresh nemolizumab results in pediatric atopic dermatitis, and the ALASTIN Signature Practices rollout. See our latest analysis for Galderma Group. The latest clinical readouts and the ALASTIN Signature Practices launch come after a mixed year for the shares, with a 5.83% 1 month share price return, a 3.27% 3 month share price decline, and a 1 year total...